Alpine Immune Sciences Inc. said it is in a clinical trial collaboration and supply agreement with Merck.
The company said the collaboration will evaluate the safety and efficacy of Alpine's ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck's anti-PD-1 therapy Keytruda pembrolizumab.
The clinical trial began dosing study participants in June.
Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.